Neoprofen Solution
NDC Package 55292-122-52

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings

Package Information

Neoprofen (ibuprofen lysine) solution is neoProfen is indicated to close a clinically significant patent ductus arteriosus (PDA) in premature infants weighing between 500 and 1500 g, who are no more than 32 weeks gestational age when usual medical management (e.g., fluid restriction, diuretics, respiratory support, etc.) is ineffective. This formulation utilizes a solution delivery system. Marketed by Recordati Rare Diseases Inc., this product is identified by NDC 55292-122 and is authorized under FDA application NDA021903.

Identification & Billing

NDC Package Code
55292-122-52
Package Description
3 VIAL in 1 CARTON / 2 mL in 1 VIAL
Product Code
11-Digit Billing Format
55292012252
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Neoprofen
Non-Proprietary Name
Ibuprofen Lysine
Substance Name
Ibuprofen Lysine
Dosage Form
Solution - A clear, homogeneous liquid1 dosage form that contains one or more chemical substances dissolved in a solvent or mixture of mutually miscible solvents.
Administration Route
Intravenous - Administration within or into a vein or veins.
Active Ingredient(s)
Usage Information
NeoProfen is indicated to close a clinically significant patent ductus arteriosus (PDA) in premature infants weighing between 500 and 1500 g, who are no more than 32 weeks gestational age when usual medical management (e.g., fluid restriction, diuretics, respiratory support, etc.) is ineffective. The clinical trial was conducted among infants with an asymptomatic PDA. However, the consequences beyond 8 weeks after treatment have not been evaluated; therefore, treatment should be reserved for infants with clear evidence of a clinically significant PDA.

Regulatory & Marketing

Labeler Name
Recordati Rare Diseases Inc.
Product Type
Human Prescription Drug
FDA Application #
NDA021903
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
04-13-2006
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 55292-122-52 identifies a specific commercial package of 3 vial in 1 carton / 2 ml in 1 vial of Neoprofen, a human prescription drug labeled by Recordati Rare Diseases Inc.. This solution is formulated for intravenous use and contains ibuprofen lysine as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Recordati Rare Diseases Inc. on April 13, 2006. The current certification is valid through December 31, 2026.

How is this Recordati Rare Diseases Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 55292012252. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
55292-122-52
11-Digit CMS (5-4-2)
55292-0122-52

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.